Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

FOLFOX4

Phase 1Small molecule

FOLFOX4 is one of 36 small molecule programs targeting Rectum Cancer. It is currently in Phase 1.

1

Indications

12

Total Trials

2

Active Trials

35

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectum CancerRecruiting

Rectum CancerPhase 1

Recruiting

Competition

Competitive Landscape

35 competitors in Rectum Cancer

#DrugCompanyPhaseTrials

Elunate

Bayer Aspirin

Crestor

Eloxatin

Stivarga

Koselugo

Rydapt

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Adrucil

Ethyol

LLegacy Health System

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Hepatocellular Carcinoma

NCT06893887

Q1 2029

Phase 1Recruiting

Rectum Cancer

NCT05912075

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma3 trials

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn·GGuangxi Medical University·Phase 2/3·NCT02527772

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Withdrawn·GGuangxi Medical University·Phase 2/3·NCT02534337

Chemotherapy2 trials

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03092895·157 enrolled

Chemotherapy Combined With CIK Treating Colon Cancer

Completed·UUnknown Sponsor·Phase 4·NCT03084809·46 enrolled

Adenocarcinoma1 trial

Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT00580073·6 enrolled

PD-1 Inhibitor1 trial

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03605706·396 enrolled

HCC1 trial

HR Combined With FOLFOX4 for HCC With PVTT

Unknown status·SSun Yat-sen University·Phase 2·NCT02452853·51 enrolled

4 more indications

Colorectal Cancer1 trial

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Unknown status·FFudan University·Phase 4·NCT00874406·100 enrolled

Rectal Carcinoma1 trial

Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)

Completed·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT02000050·52 enrolled

Rectum Cancer1 trial

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT05912075·78 enrolled

Liver Cancer1 trial

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02069041·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for FOLFOX4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

Related News